|
Dec 23
|
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|
|
Dec 19
|
Regeneron says study data support big bet on new blood thinners
|
|
Dec 19
|
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
|
|
Dec 18
|
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
|
|
Dec 18
|
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
|
|
Dec 17
|
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Dec 17
|
Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial
|
|
Dec 17
|
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
|
|
Dec 17
|
Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
|
|
Dec 16
|
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
|
|
Dec 16
|
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases
|
|
Dec 13
|
Regeneron Down 15.5% Year to Date: How to Play the Stock?
|
|
Dec 13
|
Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge
|
|
Dec 12
|
Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma
|
|
Sep 30
|
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
|
|
Sep 28
|
Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
|
|
Sep 28
|
Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’
|
|
Sep 27
|
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
|
|
Sep 27
|
Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling
|
|
Sep 27
|
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
|